Have we really demonstrated the safety of Ibrutinib on standard dose? Rethinking the dose of Ibrutinib in CLL
Published
2022-04-04
Issue
Section
Articles
| This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access. The articles in Journal of Cardiovascular Disease Research are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
|
      |
Contact Information
Journal of cardiovascular Disease Research,
Publication Office
No: 763-1/A Gandhi Road-2
Vimal Guptha Residency, Nauroji Nagar- New Delhi 110029
[email protected] | Support Email : [email protected]
